OTC · Healthcare
Cardiff Lexington Corp (CDIX)
As-reported financials and recent SEC filings for Cardiff Lexington Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$11.5M
Net income
$-5.5M
Net margin
-47.7%
Diluted EPS
—
ROE
223.0%
P/E (TTM)
—
Market cap
—
Debt / equity
-7.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.5M | $8.3M | $11.9M | $10.7M | $9.9M |
| Gross profit | $7.2M | $4.4M | $8.3M | $6.6M | $6.1M |
| Operating income | $1.1M | $-193,504 | $5.2M | $3.9M | $1.7M |
| Net income | $-5.5M | $-3.3M | $3.0M | $-5.4M | $666,293 |
| Diluted EPS | — | — | — | — | $-0.14 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
424B32026-06-23
View on EDGAR →EFFECT2026-06-18
View on EDGAR →S-12026-06-11
View on EDGAR →S-82026-06-11
View on EDGAR →8-K2026-06-11
View on EDGAR →10-Q2026-05-13
View on EDGAR →AW2026-05-12
View on EDGAR →RW2026-04-30
View on EDGAR →Largest Healthcare peers
Go deeper on CDIX
Search Cardiff Lexington Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.